

Su Jung Song

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9086296/publications.pdf>

Version: 2024-02-01

22
papers

2,155
citations

430874

18
h-index

677142

22
g-index

22
all docs

22
docs citations

22
times ranked

4331
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis. <i>Cell Metabolism</i> , 2021, 33, 2380-2397.e9. | 16.2 | 73 |
| 2 | Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. <i>Nature Communications</i> , 2019, 10, 3716. | 12.8 | 19 |
| 3 | PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. <i>Nature Communications</i> , 2019, 10, 636. | 12.8 | 53 |
| 4 | A muscle-specific UBE2O/AMPK \pm 2 axis promotes insulin resistance and metabolic syndrome in obesity. <i>JCI Insight</i> , 2019, 4, . | 5.0 | 12 |
| 5 | miR-218 and miR-129 regulate breast cancer progression by targeting Lamins. <i>Biochemical and Biophysical Research Communications</i> , 2018, 496, 826-833. | 2.1 | 32 |
| 6 | New Insights into the Role of E2s in the Pathogenesis of Diseases: Lessons Learned from UBE2O. <i>Molecules and Cells</i> , 2018, 41, 168-178. | 2.6 | 23 |
| 7 | A UBE2O-AMPK \pm 2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. <i>Cancer Cell</i> , 2017, 31, 208-224. | 16.8 | 98 |
| 8 | A new duet in cancer biology: AMPK the typical and UBE2O the atypical. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1304846. | 0.7 | 5 |
| 9 | MicroRNA, an Antisense RNA, in Sensing Myeloid Malignancies. <i>Frontiers in Oncology</i> , 2017, 7, 331. | 2.8 | 3 |
| 10 | Tetraspanins: Spanning from solid tumors to hematologic malignancies. <i>Experimental Hematology</i> , 2016, 44, 322-328. | 0.4 | 34 |
| 11 | miR-22 in tumorigenesis. <i>Cell Cycle</i> , 2014, 13, 11-12. | 2.6 | 25 |
| 12 | MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia. <i>Current Opinion in Hematology</i> , 2014, 21, 276-282. | 2.5 | 11 |
| 13 | Vulnerabilities of <i>PTEN</i> and <i>TP53</i> -Deficient Prostate Cancers to Compound PARP and PI3K Inhibition. <i>Cancer Discovery</i> , 2014, 4, 896-904. | 9.4 | 88 |
| 14 | The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation. <i>Cell Stem Cell</i> , 2013, 13, 87-101. | 11.1 | 288 |
| 15 | MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling. <i>Cell</i> , 2013, 154, 311-324. | 28.9 | 417 |
| 16 | A metabolic pro-survival role for PML in breast cancer. <i>Journal of Clinical Investigation</i> , 2012, 122, 3088-3100. | 8.2 | 220 |
| 17 | Nuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex in a Phosphatase-Independent Manner. <i>Cell</i> , 2011, 144, 187-199. | 28.9 | 333 |
| 18 | MST1 Limits the Kinase Activity of Aurora B to Promote Stable Kinetochores-Microtubule Attachment. <i>Current Biology</i> , 2010, 20, 416-422. | 3.9 | 48 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Aurora A-Mediated Phosphorylation of RASSF1A Maintains Proper Cytokinesis by Recruiting Syntaxin16 to the Midzone and Midbody. <i>Cancer Research</i> , 2009, 69, 8540-8544. | 0.9 | 36 |
| 20 | Aurora A Regulates Prometaphase Progression by Inhibiting the Ability of RASSF1A to Suppress APC-Cdc20 Activity. <i>Cancer Research</i> , 2009, 69, 2314-2323. | 0.9 | 49 |
| 21 | The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. <i>EMBO Journal</i> , 2008, 27, 1863-1874. | 7.8 | 121 |
| 22 | Role of the Tumor Suppressor RASSF1A in Mst1-Mediated Apoptosis. <i>Cancer Research</i> , 2006, 66, 2562-2569. | 0.9 | 167 |